{
  "docId": "019de073-cc15-73cb-b985-dc28972c4284",
  "docSlug": "df7f4367d54f16f4cdacd02ff486e30b",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 20,
  "pageCount": 31,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/20",
  "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284",
  "deckJsonHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284.json",
  "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.4,
        "y": 0.8
      },
      "kind": "callout",
      "text": "PRIMARY ENDPOINT: All-cause mortality at 2 weeks",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1df76e2a-9dd4-4fb5-9a0f-fc8d6cc08e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Clinical trial flow diagram showing screening, randomization, and treatment arms over 10 weeks.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46fd0d27-5003-4c19-aef5-de0299757209",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.58,
        "y": 0.78
      },
      "kind": "list",
      "text": "Key Secondary Efficacy Endpoint: Survival time through 10 weeks without Cryptococcus culture-positive relapse of meningitis. Other Secondary Endpoints include: Incidence of Grade 3-5 lab AEs, Rate of CSF Cryptococcus clearance (EFA), CSF culture sterility, 10-week survival time, Use of rescue/additional IV AMB",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07ff2699-f619-4d63-922a-75fb7fdc01b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.2,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "list",
      "text": "~270 participants; 4 sites in Uganda; Study Initiation Q1 2023; NDA Filing H1 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3557469-35ce-4b61-98b3-e453c5058b41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Assess MAT2203 as step-down therapy after 2 days of IV AMB for the Treatment of Cryptococcal Meningitis. Validate results observed in EnACT. Randomized 1:1:1 ratio to 1 of 2 MAT2203 arms or SoC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e93ebb3-2f7c-4c9a-8d5d-4ba0c433dc5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase III Pivotal Study Design – To Initiate Q1 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11036eb2-dfc8-44e5-818a-c8e5e8fe2ed6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "d5711048-fff0-4e0b-b375-17b2f61c89e6",
      "evidence": "Standardized representation of patient randomization and treatment arms over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4dd339dc-619c-4f93-88e3-a04049ef8ad7",
      "evidence": "Slides 20-21 present the value proposition for MAT2203",
      "position": 1,
      "objective": "What is the potential for MAT2203 in the market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}